A insulin aspart dose titration study using continuous subcutaneous insulin infusion (CSII) in oral antidiabetic drug-treated subjects with type 2 diabetes followed by a 10 week out patient maintenance phase.

Trial Profile

A insulin aspart dose titration study using continuous subcutaneous insulin infusion (CSII) in oral antidiabetic drug-treated subjects with type 2 diabetes followed by a 10 week out patient maintenance phase.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Oct 2016

At a glance

  • Drugs Insulin aspart (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Jun 2009 Actual patient number (71) added as reported by ClinicalTrials.gov.
    • 16 Jun 2009 Actual initiation date changed from 1 Jan 2006 to 1 Jun 2005 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top